Aviva invests in technology that detects early signs of cancer
Aviva Ventures, Aviva plc's venture capital arm, has invested in Owlstone Medical Ltd, a medical diagnostics company developing a breathalyser that can detect diseases at a very early stage.
The company is currently developing tests for lung and colorectal cancer, two of the most common terminal cancer conditions worldwide. Aviva Ventures' investment takes Owlstone Medical's total funding to $23.5 million USD (£19.3 million GBP) since its spin out of Owlstone Inc in 2016. Aviva Ventures provides early stage investment to back entrepreneurs with high growth businesses and, over time, expects to have a portfolio of small investments in a number of companies which have significant...
More on PMI
Demand for PMI to rise during 2021: AMII
New research with The Exeter
COVER Excellence Awards 2021 now open for nominations!
Leading With Distinction
Lifepoint Healthcare acquires Just Private Medical
Adds 120 clients
AMII welcomes Voyager Insurance Services
Newest member
